Gilead SciencesGILD

A U.S. Court of Appeals upheld a ruling that prevents certain health programs from importing Gilead medications from other countries to save money. These groups, known as alternative funding programs, often try to lower costs for employers by sourcing drugs from overseas markets where prices are lower.

This is a win for Gilead because it protects the company's ability to charge U.S. prices for its specialized treatments. By blocking these imports, the court is helping to close a loophole that was beginning to divert revenue away from the company's domestic business. If this ruling leads to a broader pullback in these types of programs, it would strengthen Gilead's control over its most profitable market.

Source: CNBC

HIV drug sales drive 10 percent growth in base business

California's highest court ruled in favor of Gilead in a case that could have changed how drug companies decide which medicines to develop. Patients had argued that Gilead should have brought a newer, potentially safer HIV treatment to market sooner. The court disagreed, stating that as long as a drug is safe, the manufacturer does not have a legal duty to invent a better one on a specific timeline.

This is a win for Gilead because it limits the company's legal liability for how it manages its product pipeline. If the ruling had gone the other way, it could have opened the door for lawsuits whenever a company chooses to stick with an existing product rather than spending money to launch a newer version. This provides more certainty for Gilead as it manages the transition between its older antiviral patents and its newer therapies.

Source: Reuters

The European Medicines Agency's medical committee issued a positive opinion on using Trodelvy in combination with another drug to treat triple-negative breast cancer. This type of cancer is often harder to treat because it does not respond to common hormone therapies.

This recommendation is a step toward full marketing approval in Europe. Expanding the use of Trodelvy is a central part of Gilead's plan to grow its oncology business. As the company looks to move beyond its core HIV treatments, getting these cancer therapies approved for more patients in more regions is the primary way it will replace revenue from older drugs.

Source: Business Wire

Gilead and Merck reported that their experimental once-weekly pill worked as well as daily treatments in two Phase 3 trials, which are the final large-scale tests required before a drug can be sold. The treatment uses a combination of two drugs, islatravir and lenacapavir, to keep the virus at undetectable levels in adults who were already stable on other therapies.

If approved, this would be the first once-weekly oral regimen for HIV. Moving from a daily pill to a weekly one is a major shift that could help patients stay on their medication more easily. For Gilead, this success helps protect its dominant position in the HIV market by offering a more convenient option before its older daily pills face competition from cheaper generic versions.

Source: Reuters